Neuroscience

Raman Research Fellowship

Application form for FY 2025-2026

Application Reference No. : AB-CSIR/613/2023-ISTAD-CSIR HQ/ 44

Name

Dr.

Sonia

Verma
Designation Scientist
Lab / Instt CSIR-Central Drug Research Institute(CSIR-CDRI), Lucknow
Area of research Neuroscience
Date of Birth 01-02-1988
Age not exceeding 45 yrs. as on Jan 30, 2025

Year

36

Month

5
Date Of Joining CSIR With Designation

Date of Joining CSIR

2021-06-23

Designation (At the time of joining CSIR)

Scientist
Qualification

Degree

Doctor of Philosophy

Board / University

National Institute of Immunology

Division

First

Subject

Life Sciences

Year

2019

,

Degree

Master of Science

Board / University

University of Delhi

Division

First

Subject

Biomedical Sciences

Year

2012

,

Degree

Bachelor of Science (Hons.)

Board / University

University of Delhi

Division

First

Subject

Microbiology

Year

2009
Whether belonging to SC/ST/OBC Others
Knowledge Of Foreign Languages

Language

English

Select Language

Can Speak

Can Read

Can Write
Experience

Position Held

Scientist-I

Duration

From

2016-10-20

To

2021-06-19

Nature of Work

1. Flow-cytometry based immune profiling of Patients’ samples.
2. Guidance to Junior and Senior Residents for Short-term projects.
3. Research
4. Transcriptomics, small RNA sequencing analysis
Number Of Publications

International

4

National

0
Number Of Patents

National

0

International

0
Number Of Books

National

0

International

1 (Book Chapter)
Awards & Recognition

National

0

International

0
Research, Development And Innovation Output Of The Candidate. A) Details Of Technologies And Products / Services
License Fee Received And Royalty Received
Skill Development

Select Year

2024 - 2025

Area Covered

Masters Dissertation

No. of people

4

,

Select Year

2023 - 2024

Area Covered

Masters Dissertation

No. of people

2

,

Select Year

2022 - 2023

Area Covered

Masters Dissertation

No. of people

2

,
Socio-Economic Interventions
Major achievements/contribution of international level in the proposed area of research Aspiring to Achieve the same
Enclose file, if any
Name of the host Professor/Guide and full address of the Foreign Instt/Univ/R&D lab Xing Wang, Ph.D. , (Address Nucleic Acids Programming Lab DCL 3110 (lab), 3220-3225 (office) 1304 W. Springfield Ave Bioengineering office EL Building 0250 1406 W. Green St University of Illinois, Urbana-Champaign Urbana, IL 61801)
Acceptance letter of host institute Acceptance_Letter.pdf (93.17 KB)
Research accomplishments of the host Dr. Xing Wang is a biochemist and bioengineer at University of Illinois at UrbanaChampaign (UIUC). His research group utilizes nucleic acids and protein engineering to create and customize designer DNA nanostructure-based “plug-and-play” platforms for bioengineering and bio-nanotechnology applications centered on human health. He also has expertise on RNA-mediated genome programming and cellular engineering, RNA chemistry and biology. Dr. Wang is the inventor of the ”DNA Star” platform. He is a winner of Mikashi Award in 2021. His Nucleic Acids Programming Lab (NAPL) is well funded to support the research focusing on the creation and development of (1) effective therapeutic candidates and targeted drug/mRNA delivery platforms for cancer treatment and immunotherapy, as well as inhibition and prevention of viral infections, (2) ultrasensitive and inexpensive biosensors for rapid, simple, and amplification free disease diagnostics in point-of-care, self-testing, and laboratory-based high-throughput settings, (3) machine learning model and pipelines to rapidly obtain new ligands for targeted drug delivery, and (4) molecular barcodes for multiplexing and high resolution biosensing and imaging. Dr. Wang is a co-director of the Center for Pathogen Diagnostics (CPD). His research group is currently supported by the National Institutes of Health (NIBIB, NIAID, NIDCR, NIAAA, NCI) and National Science Foundation (NSF).
Publications: 61
Patents: 5
Major research facilities at the host laboratory/institute In vitro aptamer selection pipeline, DNA nanostructure design pipeline, Surface Plasmon Resonance, Flow cytometry, NGS facility, cell culture facility
Prior linkage/cooperation with the host Spouse is a Post-Doc in the same lab.
Reason for selecting the proposed host 1. Expertise in DNA Nanotechnology:
Dr. Xing Wang is a renowned biochemist and bioengineer specializing in DNA nanotechnology. His lab focuses on creating and developing designer DNA nanostructures for various applications, including therapeutic candidates and targeted drug/mRNA delivery platforms. His extensive experience in this field is crucial for the proposed project on developing ssDNA aptamers and DNA origami nanostructures to combat ferroptosis during neuroinflammation.
2. State-of-the-Art Facilities and Resources:
Dr. Wang’s lab at the University of Illinois at Urbana-Champaign (UIUC) is equipped with state-of-the-art facilities for nucleic acids programming and DNA nanotechnology. Access to these resources will be invaluable for advancing the research project, allowing for the development and testing of innovative therapeutic strategies.
3. Proven Track Record in Aptamer Development:
Dr. Wang has developed a well-established SELEX pipeline for the selection and development of highly specific DNA aptamers. This expertise is directly aligned with the project's objectives of developing aptamers targeting DMT1 and ACSL4 to inhibit ferroptosis and neuroinflammation.
4. Innovative Research Contributions:
Dr. Wang has made significant contributions to the field of DNA nanotechnology and bio-nanotechnology. His work includes the development of ultrasensitive biosensors, designer DNA nanostructures for viral inhibition, and innovative drug delivery systems. These innovative approaches align with the goals of the proposed research, which aims to develop novel aptamer-based therapies for neuroinflammation and ferroptosis.
Dr. Wang's proven track record in developing designer DNA nanostructures for viral inhibition, innovative biosensors for disease diagnostics, and therapeutic candidates for targeted drug delivery highlights the potential impact and translational nature of the proposed research. Therefore, conducting this research at UIUC is justified to leverage these advanced capabilities and expertise for successful project outcomes.
Title of the research proposal to be carried out abroad NANOFERROBLOCK: DNA Origami Nanostructures Equipped with ssDNA Aptamers as DMT1 and ACSL4 Inhibitors for Combating Ferroptosis during Neuroinflammation
Detailed description of the research work to be carried out abroad Enclosed
Enclose separate sheet Research Proposal.pdf (597.81 KB)
Please give one page write-up on the novelty of the research topic 1. Dual Targeting Approach:
The study proposes using ssDNA aptamers to simultaneously target DMT1 and ACSL4, two critical proteins involved in ferroptosis and neuroinflammation. This dual targeting strategy is innovative as it addresses both iron accumulation and phospholipid peroxidation, the two key processes driving ferroptosis in microglia. By inhibiting both pathways, the approach promises a more comprehensive and effective strategy to mitigate neuroinflammation.
2. DNA Origami Nanostructures:
Utilizing DNA origami nanostructures to arrange ssDNA aptamers represents a novel method to enhance the specificity and efficacy of the treatment. DNA origami allows for precise spatial arrangement and multi-valent binding, which can significantly improve the interaction between the aptamers and their target proteins. This method not only enhances the binding affinity but also increases the stability and bioavailability of the aptamers, making the treatment more effective and durable.
3. Innovative SELEX Pipeline:
The research leverages a well-established SELEX pipeline to develop highly specific ssDNA aptamers. The SELEX process ensures the selection of aptamers with exceptional affinity and specificity for DMT1 and ACSL4. The combination of SELEX with next-generation sequencing further refines the selection process, enhancing the quality of the aptamers developed.
4. Combating Ferroptosis:
The project's focus on inhibiting ferroptosis in microglia to combat neuroinflammation and neurodegeneration is innovative and holds significant potential for developing new treatments for a range of neurological disorders. This approach is particularly relevant given the growing recognition of ferroptosis as a key player in neuroinflammatory processes.
5. Potential for Broad Application:
The aptamers and DNA nanostructures developed in this project have the potential to be adapted for other diseases characterized by ferroptosis such as breast and bone cancers. This broad applicability enhances the novelty of the research, as it opens new possibilities for treating various conditions beyond neurodegenerative diseases, including certain cancers and cardiovascular diseases.
6. Collaborative and Cutting-Edge Research Environment:
Conducting the research in collaboration with Dr. Wang's lab, which specializes in DNA nanotechnology and SELEX, ensures access to state-of-the-art equipment and expertise. This collaboration not only enhances the technical quality of the research but also fosters innovative thinking and cross-disciplinary approaches, further contributing to the novelty of the project.
Linkage of the proposed work with priority Themes/Projects/Programmes of CSIR HealthCare
Does the proposed research work involve IPR issues. If yes, has the host institute agreed to share the same with CSIR? No
Could the proposed work be carried out within India at CSIR/non CSIR S&T institutions? An integrated set up combining aptamer selection pipeline, NGS sequencing, SPR, flow cytometry combing with well standardized protocol at Wang Lab makes it an ideal avenue.
1. Access to Advanced Facilities and Resources:
Dr. Xing Wang's lab is equipped with advanced tools and technologies for nucleic acids programming, DNA nanotechnology, and aptamer development, which are essential for the project's success.

2. Expertise in DNA Nanotechnology:
Dr. Wang is a leading expert in DNA nanotechnology, with extensive experience in designing and synthesizing functional DNA nanostructures. His expertise will provide invaluable insights and technical support, ensuring the successful development of the proposed DNA origami nanostructures and ssDNA aptamers.

3. Innovative SELEX Pipeline:
The established SELEX pipeline in Dr. Wang's lab allows for the efficient selection and development of highly specific ssDNA aptamers.

4. Comprehensive Research Support:
Dr. Wang's lab is supported by substantial funding from prestigious organizations such as the NIH and NSF, ensuring that the research project will have access to necessary financial and technical resources.

5. Training and Mentorship:
The research environment at UIUC, under the mentorship of Dr. Wang, will provide rigorous training in cutting-edge techniques and methodologies.

6. Real-World Impact:
The outcomes of the proposed research have the potential to develop novel therapeutic strategies and diagnostic tools for neurodegenerative diseases, which could significantly impact healthcare systems globally. Conducting this research at UIUC, with its focus on translational research and real-world applications, will ensure that the findings are effectively translated into practical solutions.

(Host CV Enclosed)
Please enclose separate sheet, if necessary Host CV.pdf (146.29 KB)
Minimum period required for conducting proposed research. (2-6 months) 6 months
Relevance of proposed research with the activities/programmes of Lab/CSIR The proposed research is highly relevant to CDRI’s and CSIR’s vision and mission, addressing critical health challenges through innovative science and technology.
1. Technology Innovation and Translational Research:
The development of ssDNA aptamers for targeting DMT1 and ACSL4 represents a significant technological innovation. This research aligns with CSIR’s goal of advancing technology innovation and translating research into practical applications.
2. Development of National Strengths:
The expertise gained in DNA nanotechnology and aptamer development strengthens India’s position in advanced biotechnological solutions, contributing to national strengths in cutting-edge research.
3. Synergizing Diverse Expertise:
This research integrates biology, chemistry, and nanotechnology, addressing grand challenges in neuroscience and demonstrating the commitment to solving complex scientific problems through interdisciplinary collaboration.
4. Globally Benchmarked Processes:
The use of advanced SELEX technology and collaboration with international experts ensures that the research meets global standards, promoting India’s position in the international scientific community.
5. Catalyzing Sustainable Production:
The scalable and cost-effective nature of aptamer production aligns with the goal of optimizing sustainable processes for reducing healthcare costs.
6. Capacity Building:
The project will build specialized knowledge and skills in aptamer technology and DNA nanotechnology, contributing to the objective of enabling globally competitive R&D.
Nature of expected output from the proposed study and its likely uses Aptamer Development: The research experience is anticipated to yield the successful development of DNA origami nanostructures loaded with novel ssDNA aptamers designed to target specific molecular elements crucial in neuroinflammation, such as DMT1 and ACSL4, the two proteins promoting ferroptosis. These aptamers are expected to act as inhibitors of ferroptosis during neuroinflammation.
Expertise in DNA Nanotechnology: The project will build specialized knowledge and skills in aptamer development technology, including the design, selection, and biochemical modification of aptamers.
Collaborative Research Opportunities: The project will provide collaborative research opportunities with institutions and researchers globally.
Accelerated Development and Broad Applicability: The use of aptamers allows for a rapid and cost-effective aptamer development process and can be used to target similar proteins in other diseases.
Aptamer-Based Diagnostic Tools: The aptamers developed can also be used to create diagnostic tools for disease diagnosis, prognosis, and monitoring of treatment effectiveness.
Commercial and Clinical Opportunities: The aptamers developed can be of interest to pharmaceutical companies for further pre-clinical and clinical studies.
Scientific Publications: The findings and outcomes can be disseminated through scientific publications, contributing to the global knowledge base in aptamer technology and its applications.
What benefits will accrue to CSIR by conducting this research work Conducting the research will significantly benefit CSIR by advancing its expertise in aptamer technology and innovative neuroinflammation therapies, which aligns with its mission to enhance R&D capabilities and improve health outcomes in India. The project will facilitate global collaborations, leading to commercial and clinical opportunities, and contribute to the development of diagnostic tools. Additionally, the research findings will enhance CSIR's reputation through scientific publications and knowledge dissemination.
Commercialisation prospects of the proposed research work Therapeutic Applications: As innovative inhibitors of ferroptosis during neuroinflammation, these aptamers have the potential to be developed into new therapies for treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. This can attract pharmaceutical companies interested in novel treatment modalities for these conditions.
Diagnostic Tools: The high specificity and stability of aptamers make them ideal candidates for developing diagnostic assays, which can be marketed to clinical laboratories and healthcare providers.
Customized Aptamer Development: The expertise gained in aptamer technology can be leveraged to develop customized aptamers targeting other disease-related proteins. This service can be offered to other research institutions and biotech companies, creating a new business line for CSIR.
Biotechnology Products: The DNA origami nanostructures themselves represent a novel biotechnology product. These structures can be marketed for various applications beyond neuroinflammation, including targeted drug delivery systems, biosensors, and nanomedicine.
Global Market Potential: Neurodegenerative diseases are a growing concern globally, with significant market potential for effective therapies and diagnostic tools. By tapping into this market, CSIR can position itself as a leader in this innovative field, attracting international investments and partnerships.
Previous visits abroad during last 3 years One in 2023 (Non-Official)
Any other relevant information you may feel necessary to give None
signature Signed_Application.pdf (309.04 KB)
Recommendations Of The Director Of The Lab/Instt
a) Comments of the Director on the information given above by the applicant. Dr. Sonia Verma has submitted a comprehensive and well-structured application titled "NANOFERROBLOCK: DNA Origami Nanostructures Equipped with ssDNA Aptamers as DMT1 and ACSL4 Inhibitors for Combating Ferroptosis during Neuroinflammation," for the Raman Research Fellowship for the year 2024-2025. This is a highly innovative proposal with high translational potential. It is well thought out and systematic. Developing aptamers that can limit neuroinflammation could lead to novel therapeutic interventions that are specific, effective, and safe.
b) Remark of the Director on the potential and credentials of the applicant Dr. Sonia Verma is working as a Scientist at the division of "Neuroscience & Ageing Biology" in CSIR-Central Drug Research Institute since June, 2021. Her major research focuses on delineate the role of novel targets in neurodegeneration and neuroinflammation. In a short span of time, Dr. Verma has developed primary/secondary assays for screening and identifying molecules targeting mitochondrial biogenesis leading to neuroinflammation and neurodegeneration. I am confident that her work will contribute immensely to new knowledge generation and also have a meaningful impact on the development of therapeutics for neuroinflammation and neurodegenration. One of the most striking aspects of Dr. Verma's work is her interdisciplinary approach. She is well suited for this unique opportunity and I am confident that her work will yield some interesting new avenues of exploration for the future. I strongly recommend her to this program.
c) Field of proposed study and its relation to the Lab's Priorities, particularly with regards to the Priority Themes/Projects/Prog The proposed study aligns well with the priorities of CSIR-CDRI. This research is pertinent to the institute's focus on developing innovative therapeutic strategies for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's and Parkinson's represent major public health challenges due to their increasing prevalence and the lack of effective treatments. The research also fits well with CDRI’s interest in understanding the rolw of inflammation in neurodegeneration.
Further, the research aligns with CSIR-CDRI’s mission to foster technological innovation and translational research. The development of such advanced therapeutic strategies not only enhances the institute’s research capabilities but also positions it at the forefront of neurodegenerative disease research globally. The project’s interdisciplinary approach, integrating biology, chemistry, and nanotechnology, exemplifies the kind of translational research that CSIR-CDRI prioritizes.
d) Remarks on chosen place of work, special features of the concerned Lab The selection of Dr. Xing Wang’s lab at the University of Illinois Urbana-Champaign (UIUC) is well-justified due to its state-of-the-art facilities and expertise in DNA nanotechnology and aptamer development. Dr. Wang’s lab is renowned for its pioneering work in nucleic acids and protein engineering, making it an ideal environment for advancing the proposed research. The lab's cutting-edge infrastructure includes advanced tools and technologies essential for DNA nanostructure design, SELEX pipeline, surface plasmon resonance, and NGS facilities. These resources are critical for the successful execution of Dr. Verma’s research project.
Furthermore, Dr. Wang’s lab has a proven track record of innovative research in DNA nanotechnology, particularly in creating and customizing designer DNA nanostructures for various bioengineering applications. This includes the development of DNA origami structures that can be utilized to enhance the delivery and efficacy of therapeutic aptamers. The opportunity to work with such advanced DNA nanostructures will provide Dr. Verma with hands-on experience in cutting-edge nanotechnology, significantly enhancing her research capabilities and expertise.
e) Scientific and economic implication of the proposed work during the Fellowship (both on Indian as well as global) The proposed research aims to develop novel therapeutic strategies that can inhibit ferroptosis, thereby potentially halting or reversing the damage caused by chronic neuroinflammation. This innovative approach not only offers a deeper insight into the mechanisms driving neurodegenerative diseases but also paves the way for the creation of highly specific and effective treatments.
The development of new aptamer-based therapies represents a breakthrough in precision medicine. Aptamers, which are single-stranded DNA or RNA molecules, can be designed to bind with high specificity and affinity to target proteins involved in neuroinflammation and ferroptosis. This specificity reduces the likelihood of off-target effects and increases the therapeutic efficacy, making aptamers a promising alternative to traditional small molecule drugs and antibodies.
Moreover, the commercialization prospects of these novel therapies are substantial. Successful development and validation of these aptamer-based treatments can attract interest from pharmaceutical companies looking for innovative solutions to tackle not only neurodegenerative diseases but other conditions where ferroptosis is involved. This creates opportunities for CSIR to license these technologies and collaborate with industry partners, facilitating the translation of research findings into clinical applications. Such collaborations can lead to the development of new diagnostic tools and therapeutic products, generating revenue for CSIR through licensing agreements and fostering the growth of biotechnology sectors within India.

Nature of expected output from the proposed study.
The expected outputs include:
1. Development of DNA origami nanostructures loaded with ssDNA aptamers targeting DMT1 and ACSL4.
2. Detailed characterization of these aptamers and their efficacy in inhibiting ferroptosis and neuroinflammation.
3. High-impact scientific publications and potential patents.
4. Enhanced capacity in the field of DNA nanotechnology and aptamer development.
f) Commercialisation prospect and likely users of the proposed research in the industrial sectors The goal of the current research is to establish proof-of-concept using DNA Origami Nanostructures Equipped with ssDNA Aptamers for combating Ferroptosis during Neuroinflammation. The results of the project could leads for drug discovery and diagnostics. There would be potential applications in multiple disease areas and commercial interest would be very likely from the Pharma and Biotech industry
g) List of scientific peers, who can appreciate and comment on the scientific approach and overall utlity of the proposed work Dr. Arjun Ramakrishnan, IIT Kanpur
Dr. Subhas Biswas, IICB Kolkata
Dr. Jayanta Chatterjee, IISc Bengaluru
Recommendations of the Director of the Lab/Instt Director_Recommendations.pdf (849.92 KB)
Summary Sheet of the RRF Applicant fill Annexure III of the RRF Guidelines Summary_and_Publication_ Details.pdf (4.05 MB)

Neuroscience

Raman Research Fellowship

Application form for FY 2025-2026

Subscribe to CSIR Daily News Bulletin, Enter Your Email ID

Accessibility options by UX4G